Department of Internal Medicine, Nova Southeastern University, Fort Lauderdale.
Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University.
Coron Artery Dis. 2024 Nov 1;35(7):584-589. doi: 10.1097/MCA.0000000000001390. Epub 2024 May 27.
Patients with cardiovascular disease (CVD) and risk factors have increased rates of adverse events and mortality after hospitalization for coronavirus disease 2019 (COVID-19). In this study, we attempted to identify and assess the effects of CVD on COVID-19 hospitalizations in the USA using a large national database.
The current study was a retrospective analysis of data from the US National (Nationwide) Inpatient Sample from 2020. All adult patients 18 years of age and older who were admitted with the primary diagnosis of COVID-19 were included. The primary outcome was in-hospital mortality, while secondary outcomes included prolonged hospital length of stay, mechanical ventilation, and disposition other than home. Prolonged hospital length of stay was defined as a length of stay greater than the 75 th percentile for the full sample. The diagnoses were identified using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes.
A total of 1 050 040 patients were included in the study, of which 454 650 (43.3%) had prior CVD. Patients with CVD had higher mortality during COVID-19 hospitalization (19.3 vs. 5.0%, P < 0.001). Similarly, these patients had a higher rate of prolonged hospital length of stay (34.5 vs. 21.0%, P < 0.001), required mechanical ventilation (15.4 vs. 5.6%, P < 0.001), and were more likely to be discharged to a disposition other than home (62.5 vs. 32.3%, P < 0.001). Mean hospitalization cost was also higher in patients with CVD during hospitalization ($24 023 vs. $15 320, P < 0.001). Conditional logistic regression analysis showed that the odds of in-hospital mortality [odds ratio (OR), 3.23; 95% confidence interval (CI), 2.91-3.45] were significantly higher for COVID-19 hospitalizations with CVD, compared with those without CVD. Similarly, prolonged hospital length (OR, 1.82; 95% CI, 1.43-2.23), mechanical ventilation (OR, 3.31; 95% CI, 3.06-3.67), and disposition other than home (OR, 2.01; 95% CI, 1.87-2.21) were also significantly higher for COVID-19 hospitalizations with coronary artery disease.
Our study showed that the presence of CVD has a significant negative impact on the prognosis of patients hospitalized for COVID-19. There was an associated increase in mortality, length of stay, ventilator use, and adverse discharge dispositions among COVID-19 patients with CVD. Adjustment in treatment for CVD should be considered when providing care to patients hospitalized for COVID-19 to mitigate some of the adverse hospital outcomes.
患有心血管疾病 (CVD) 和相关风险因素的患者在因 2019 年冠状病毒病 (COVID-19) 住院后出现不良事件和死亡的风险增加。在这项研究中,我们试图使用大型全国数据库来识别和评估 CVD 对美国 COVID-19 住院的影响。
本研究是对 2020 年美国全国 (全国) 住院患者样本的回顾性分析。所有年龄在 18 岁及以上、以 COVID-19 为主要诊断入院的成年患者均被纳入研究。主要结局是院内死亡率,次要结局包括住院时间延长、机械通气和非出院至家中的处置。住院时间延长定义为住院时间超过全样本第 75 百分位数。使用国际疾病分类,第 10 次修订版,临床修正 (ICD-10-CM) 代码确定诊断。
共有 1050040 名患者纳入研究,其中 454650 名(43.3%)患有既往 CVD。患有 CVD 的 COVID-19 住院患者死亡率更高(19.3%比 5.0%,P<0.001)。同样,这些患者的住院时间延长率(34.5%比 21.0%,P<0.001)、需要机械通气(15.4%比 5.6%,P<0.001)和更有可能出院到非家中的处置(62.5%比 32.3%,P<0.001)更高。患有 CVD 的患者在住院期间的平均住院费用也更高(24023 美元比 15320 美元,P<0.001)。条件逻辑回归分析显示,与无 CVD 的 COVID-19 住院患者相比,患有 CVD 的 COVID-19 住院患者的院内死亡率(比值比 [OR],3.23;95%置信区间 [CI],2.91-3.45)显著更高。同样,住院时间延长(OR,1.82;95%CI,1.43-2.23)、机械通气(OR,3.31;95%CI,3.06-3.67)和非家中的处置(OR,2.01;95%CI,1.87-2.21)也显著更高。
我们的研究表明,CVD 的存在对 COVID-19 住院患者的预后有显著的负面影响。患有 CVD 的 COVID-19 患者的死亡率、住院时间、呼吸机使用和不良出院处置率均升高。在为 COVID-19 住院患者提供护理时,应考虑调整 CVD 的治疗,以减轻一些不良的住院结局。